Rapamycin
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Category | Antibiotics |
Catalog number | BBF-02627 |
CAS | 53123-88-9 |
Molecular Weight | 914.19 |
Molecular Formula | C51H79NO13 |
Purity | >98% |
Catalog Number | Size | Price | Stock | Quantity |
---|---|---|---|---|
BBF-02627 | 500 mg | $199 | In stock |
Online Inquiry
Add to cartCapabilities & Facilities
Fermentation Lab
4 R&D and scale-up labs
2 Preparative purification labs
Fermentation Plant
Semi pilot, pilot and industrial plant 4 Manufacturing sites 7 Production lines at pilot scale 100+ Reactors of 30-4000 L; 170+ reactors of 20 KL-30 KL; 24+ reactors of >100 KL 2 Hydrogenation reactors (200 L, 4Mpa and 1000L, 4Mpa)
Product Description
Rapamycin is an mTOR inhibitor immunosuppressant and kinase inhibitor with both antifungal and antineoplastic properties. It selectively inhibits the transcriptional activation of cytokines.
- Specification
- Properties
- Toxicity
- Reference Reading
- Spectrum
- Price Product List
- QC Data
Synonyms | Sirolimus; (-)-Rapamycin; AY 22989; AY-22989; I-2190A; NSC 226080; RAPA; RAP; RPM; SLM; WY-090217; Everolimus EP Impurity A |
Storage | Store at -20°C |
IUPAC Name | (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone |
Canonical SMILES | CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC |
InChI | InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1 |
InChI Key | QFJCIRLUMZQUOT-HPLJOQBZSA-N |
Source | Streptomyces hygroscopicus |
Appearance | White to off-white powder |
Application | antifungal and antineoplastic agent |
Antibiotic Activity Spectrum | fungi; neoplastics (Tumor) |
Boiling Point | 973.0°C at 760 mmHg |
Melting Point | 183-185°C |
Flash Point | 542.261°C |
Density | 1.2 g/cm3 |
Solubility | Soluble in DMSO (25 mg/ml), ethanol (up to 50 mg/ml), chloroform (5 mg/ml), methanol (25 mg/ml), ether, and acetone. Limited water solubility. |
LogP | 4.3 |
Carcinogenicity | No indication of carcinogenicity to humans (not listed by IARC). |
Mechanism Of Toxicity | Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle. |
Toxicity | LD50: >800 mg/kg (oral, rat); LD50: >800 mg/kg (oral, mice). |
Predicted LC-MS/MS Spectrum - 10V, Positive

Experimental Conditions
Collision Energy: 10 eV
Instrument Type: QTOF (generic), spectrum predicted by CFM-ID
Mass Resolution: 0.0001 Da
BBF-00968 | Homoalanosine | Inquiry |
BBF-01851 | Fumagillin | Inquiry |
BBF-04609 | 1,1-Dimethylbiguanide hydrochloride | Inquiry |
BBF-01829 | Deoxynojirimycin | Inquiry |
BBF-05818 | Docosahexaenoic acid | Inquiry |
BBF-03963 | Pristinamycin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
